A. Kaltenböck

Randomized, Double‐Blind, Placebo‐Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis Vaccine

Erich Tauber, Herwig Kollaritsch, Frank von Sonnenburg et al. · The Journal of Infectious Diseases · 2008 · 94 citations · Full text

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51

Elisabeth Schuller, Bernd Jilma, V. Voicu et al. · Vaccine · 2008 · 78 citations

Vaccination, Vaccine Development, Vaccine Research +7

Immunogenicity and safety of IXIARO® (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age

A. Kaltenböck, Katrin Dubischar-Kastner, Elisabeth Schuller et al. · Vaccine · 2009 · 63 citations

Primary Immunodeficiency, Allergy, Autoimmune Disease +9

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX®1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study

A. Kaltenböck, Katrin Dubischar-Kastner, Gerald Eder et al. · Vaccine · 2009 · 57 citations

Vaccinology, Vaccine Safety, Vaccination +12

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study

Elisabeth Schuller, Christoph Klade, Gabriele Wölfl et al. · Vaccine · 2009 · 55 citations

Vaccination, Standard Regimen, Medicine +7